Heather Prichard - Humacyte Chief Officer
| HUMAW Stock | USD 1.73 0.02 1.14% |
Insider
Heather Prichard is Chief Officer of Humacyte
| Age | 47 |
| Phone | 919 313 9633 |
| Web | https://www.humacyte.com |
Heather Prichard Latest Insider Activity
Tracking and analyzing the buying and selling activities of Heather Prichard against Humacyte stock is an integral part of due diligence when investing in Humacyte. Heather Prichard insider activity provides valuable insight into whether Humacyte is net buyers or sellers over its current business cycle. Note, Humacyte insiders must abide by specific rules, including filing SEC forms every time they buy or sell Humacyte'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Heather Prichard over six months ago Acquisition by Heather Prichard of 78779 shares of Humacyte at 2.56 subject to Rule 16b-3 | ||
Heather Prichard over six months ago Acquisition by Heather Prichard of 136000 shares of Humacyte subject to Rule 16b-3 | ||
Heather Prichard over six months ago Disposition of 2625 shares by Heather Prichard of Humacyte at 9.412 subject to Rule 16b-3 | ||
Heather Prichard over six months ago Disposition of 6564 shares by Heather Prichard of Humacyte subject to Rule 16b-3 |
Humacyte Management Efficiency
The company has return on total asset (ROA) of (0.5323) % which means that it has lost $0.5323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.5081) %, meaning that it generated substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | INSIDER Age | ||
| Christian Lapointe | Quantum Si incorporated | 53 | |
| John Stark | Quantum Si incorporated | 50 | |
| Matthew Dyer | Quantum Si incorporated | 43 | |
| Michael McKenna | Quantum Si incorporated | 62 | |
| Claudia Drayton | Quantum Si incorporated | 56 | |
| Todd Rearick | Quantum Si incorporated | N/A | |
| William Scheessele | Humacyte | 53 | |
| Yang MD | Humacyte | 59 | |
| Shamik MD | Humacyte | 52 | |
| Dale Sander | Humacyte | 65 | |
| Michael MD | Quantum Si incorporated | 40 | |
Management Performance
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 |
Humacyte Leadership Team
Elected by the shareholders, the Humacyte's board of directors comprises two types of representatives: Humacyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Humacyte. The board's role is to monitor Humacyte's management team and ensure that shareholders' interests are well served. Humacyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Humacyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliana Blum, CoFounder Advisor | ||
| Harold Alterson, Senior Quality | ||
| MS MS, Chief Officer | ||
| Sabrina Osborne, Executive People | ||
| Kiernan MD, Chief Officer | ||
| Dale Sander, Chief CFO | ||
| William Scheessele, Chief Officer | ||
| Yang MD, Chief Officer | ||
| B Scheessele, Chief Officer | ||
| Shamik MD, Chief Officer | ||
| SPHR GPHR, Chief Officer | ||
| Heather Prichard, Chief Officer |
Humacyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Humacyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Number Of Shares Shorted | 9.1 K | ||||
| Gross Profit | (77.4 M) | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Total Debt | 57.51 M | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (3.16) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.